Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with First Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Curative-Intent Immunochemotherapy

Nikita Dave, Jennifer J.D. Morrissette, Stephen J. Schuster, Sunita Dwivedy Nasta, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Megan S. Lim, Daniel J. Landsburg

Blood (2022) 140 (Supplement 1): 6702–6703.

https://doi.org/10.1182/blood-2022-165073

Published: 2022

Journal Articles

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1481–1484.

https://doi.org/10.1182/blood-2022-160090

Published: 2022

Journal Articles

Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel

Blood (2022) 140 (Supplement 1): 7371–7373.

https://doi.org/10.1182/blood-2022-167601

Published: 2022

Journal Articles

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Newly-Diagnosed Germinal Center Aggressive B Cell Lymphoma

Daniel J. Landsburg, Jennifer J.D. Morrissette, Stephen J. Schuster, Sunita Dwivedy Nasta, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Megan S. Lim

Blood (2022) 140 (Supplement 1): 6653–6655.

https://doi.org/10.1182/blood-2022-165056

Published: 2022

Journal Articles

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Blood (2022) 140 (Supplement 1): 4612–4614.

https://doi.org/10.1182/blood-2022-162393

Published: 2022

Journal Articles

Low-Dose Radiation Therapy with Nivolumab in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of the Phase II Radvax Trial

Michael J. LaRiviere, Tina Vaziri, Michael Farwell, Amit Maity, Ima Paydar, Stephen J. Schuster, Sunita Dwivedy Nasta, Elise A. Chong, Daniel J. Landsburg, John P. Plastaras, Jakub Svoboda

Blood (2022) 140 (Supplement 1): 3726–3727.

https://doi.org/10.1182/blood-2022-168975

Published: 2022

Journal Articles

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Palliative-Intent Therapy

Danielle F Soberman, Jennifer J.D. Morrissette, Stephen J. Schuster, Sunita Dwivedy Nasta, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Megan S. Lim, Daniel J. Landsburg

Blood (2022) 140 (Supplement 1): 9514–9515.

https://doi.org/10.1182/blood-2022-165086

Published: 2022

Journal Articles

Rituximab, Cyclophosphamide, Etoposide and Prednisone for the Treatment of Post-Transplantation Lymphoproliferative Disorder

Reid M. Muenzen, Mitchell E. Hughes, Sunita Dwivedy Nasta, Jakub Svoboda, Daniel J. Landsburg, Stefan K. Barta, Donald Tsai, Stephen J. Schuster, Elise A. Chong

Blood (2022) 140 (Supplement 1): 6715–6716.

https://doi.org/10.1182/blood-2022-169764

Published: 2022

Journal Articles

Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas - a Phase 2 Study

Moshe Y. Levy, Deepa Jagadeesh, Zhanet Grudeva-Popova, Marek Trněný, Wojciech Jurczak, Halyna Pylypenko, Marc André, Sunita Dwivedy Nasta, Dalit Rechavi-Robinson, Sara Toffanin, Sandrine Micallef, Antoine Attinger, Elisabeth Rouits, Marie-Claude Roubaudi-Fraschini, Panos Orfanos, Mariola Dymkowska, Heidi Nauwelaerts, Sherida Woei-a-Jin

Blood (2021) 138 (Supplement 1): 526.

https://doi.org/10.1182/blood-2021-145102

Published: 2021

Journal Articles

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors

Jakub Svoboda, Hatcher J Ballard, Carrie I Ho, Mitchell E. Hughes, Elise A Chong, Adam Duca, Sara Prischak, Sunita Dwivedy Nasta, Marco Ruella, Daniel J Landsburg, Stefan K. Barta, James N Gerson, Stephen J. Schuster

Blood (2021) 138 (Supplement 1): 2445.

https://doi.org/10.1182/blood-2021-153122

Published: 2021

Journal Articles

Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas

Blood (2021) 138 (Supplement 1): 1438.

https://doi.org/10.1182/blood-2021-151766

Published: 2021

Journal Articles

Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis

Elise A. Chong, MD, Emeline R. Chong, Daniel J. Landsburg, MD, James N. Gerson, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Stefan K. Barta, MDMRCP,MS, Alfred L. Garfall, MD, Elizabeth Weber, BSN, RN, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143348

Published: 2020

Journal Articles

Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-142089

Published: 2020

Journal Articles

Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

Jakub Svoboda, MD, Stefan K. Barta, MDMRCP,MS, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Wei-Ting Hwang, PhD, Grace Delp, Brittany Amundsen, Hatcher J. Ballard, BS, James N. Gerson, MD, Elise A. Chong, MD, Mitchell E. Hughes, PharmD, Steven A. Emanuel, Marco Ruella, MD, Stephen J. Schuster, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140507

Published: 2020

Journal Articles

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Elise A. Chong, MD, James N. Gerson, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, David L. Porter, MD, Karen Dengel, BSN, RN, Don L. Siegel, MD PhD, Joan Gilmore, BS, Stefan K. Barta, MD MRCP, MS, Bruce L Levine, PhD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 594.

https://doi.org/10.1182/blood-2019-131078

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

https://doi.org/10.1182/blood-2019-128148

Published: 2019

Journal Articles

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

David M. Weiner, BA, Nathaniel D. Robinson, MD, Steven M. Bair, MD, Hatcher J. Ballard, BS, Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 5250.

https://doi.org/10.1182/blood-2019-128556

Published: 2019

Journal Articles

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Daniel J. Landsburg, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Elise A. Chong, MD, James N. Gerson, MD, Stefan K. Barta, MD MRCP, MS, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5261.

https://doi.org/10.1182/blood-2019-130039

Published: 2019

Journal Articles

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience

Sunita Dwivedy Nasta, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Elise A. Chong, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Daniel J. Landsburg, MD, Meredith I LaRose, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Marco Ruella, MD, Noelle V. Frey, MD, Stephen J. Schuster, MD, David L. Porter, MD

Blood (2019) 134 (Supplement_1): 3240.

https://doi.org/10.1182/blood-2019-130650

Published: 2019

Journal Articles

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Susan Prockop, MD, Ran Reshef, MDMSc, Donald E. Tsai, MD PhD, Nancy Bunin, MD, Rolla Abu-Arja, MD, Kris Michael Mahadeo, MD, Wen-Kai Weng, MD PhD, Koen Van Besien, MD PhD, David Loeb, MD PhD, Sunita Dwivedy Nasta, MD, Eneida R. Nemecek, MDMBA,MSc, Minoti Hiremath, MBBS, PhD, Susan Yue, MD, Yan Sun, PhD, Willis Navarro, MD, Sarah Nikiforow, MD PhD

Blood (2019) 134 (Supplement_1): 4071.

https://doi.org/10.1182/blood-2019-124904

Published: 2019

NARROW

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with First Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Curative-Intent Immunochemotherapy

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Newly-Diagnosed Germinal Center Aggressive B Cell Lymphoma

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Low-Dose Radiation Therapy with Nivolumab in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of the Phase II Radvax Trial

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Palliative-Intent Therapy

Rituximab, Cyclophosphamide, Etoposide and Prednisone for the Treatment of Post-Transplantation Lymphoproliferative Disorder

Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas - a Phase 2 Study

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors

Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas

Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis

Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis

Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only